<DOC>
	<DOCNO>NCT00003926</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Chemoprotective drug amifostine may protect normal cell side effect high-dose chemotherapy . PURPOSE : Phase I trial study effectiveness amifostine protect side effect peripheral stem cell transplantation treat patient high-risk relapse solid tumor .</brief_summary>
	<brief_title>Amifostine Protect From Side Effects PSCT Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose-limiting toxicity amifostine chemoprotection peripheral blood stem cell transplantation plus chemotherapy patient high-risk relapse solid tumor brain tumor . - Determine response time disease progression patient treat regimen . OUTLINE : This dose-escalation study amifostine . Patients stratify accord age ( 1 18 v 19 45 year ) . All patient receive filgrastim ( G-CSF ) IV 1 week . On day 6 G-CSF administration , patient undergo peripheral blood stem cell ( PBSC ) harvest follow chemotherapy . Patients receive oral busulfan every 6 hour day -8 -6 follow melphalan IV 30 minute day -5 -4 thiotepa IV 2 hour day -3 -2 . Patients receive amifostine IV 5 minute begin 30 minute prior melphalan thiotepa administration day -5 -1 . PBSC reinfused day 0 . Cohorts 3-6 patient receive escalate dos amifostine maximum tolerate dose determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow day 50 ; 3 , 6 , 9 month ; 1 , 2 , 3 year post PBSC transplantation . PROJECTED ACCRUAL : A maximum 60 patient ( 30 per stratum ) accrue study within 3 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Chordoma</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Histologically confirm highrisk relapse solid tumor brain tumor , include : Metastatic relapse Ewing 's sarcoma Metastatic relapse rhabdomyosarcoma Refractory Wilms ' tumor Diffuse anaplastic Wilms ' tumor Stage III IV neuroblastoma Recurrent retinoblastoma Metastatic relapse germ cell tumor Metastatic relapse soft tissue sarcomas Small cell ovarian sarcoma Metastatic relapse primitive neuroectodermal tumor bone Recurrent brain tumor Desmoplastic small round cell tumor Recurrent metastatic chordomas Metastatic relapse hepatoblastoma Patients receive peripheral blood stem cell transplantation complete remission good partial remission disease progression Must radiologic , nuclear image , histologic verification relapse Age 1 45 Performance status : Karnofsky 70100 % Absolute neutrophil count great 1,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin count least 10 g/dL Bilirubin le 2 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Creatinine less 2 time ULN Creatinine clearance great 70 mL/min Cardiac shortening fraction great 30 % Cardiac ejection fraction great 45 % At least 1 week since prior hematopoietic growth factor recover At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) recover Recovered prior therapy Osteogenic sarcoma Less 4 month Uncontrolled bleed Congestive heart failure Uncontrolled hypertension Asthma Pregnant nursing Uncontrolled metabolic disease Active severe infection Allergy aminothiol compound Prior bone marrow transplantation Other concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent Wilms tumor</keyword>
	<keyword>recurrent retinoblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>ovarian germ cell tumor</keyword>
	<keyword>chordoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>unresectable neuroblastoma</keyword>
	<keyword>desmoplastic small round cell tumor</keyword>
	<keyword>rhabdomyosarcoma</keyword>
	<keyword>Ewing sarcoma</keyword>
	<keyword>neuroectodermal tumor</keyword>
	<keyword>teratoma</keyword>
	<keyword>malignant testicular germ cell tumor</keyword>
	<keyword>malignant ovarian germ cell tumor</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
	<keyword>malignant germ cell tumor</keyword>
	<keyword>hepatoblastoma</keyword>
	<keyword>liver cancer</keyword>
	<keyword>medulloblastoma</keyword>
	<keyword>cerebellar astrocytoma</keyword>
	<keyword>brain stem glioma</keyword>
	<keyword>glioma</keyword>
	<keyword>cerebral astrocytoma</keyword>
	<keyword>ependymoma</keyword>
</DOC>